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Could no benefit of
cyclophosphamide treatment
be due to decreased fibrinolytic
activity in adults with severe
Henoch Scho¨nlein nephritis?
To the Editor: We read with interest the article by Pillebout
et al.1 They reported that the addition of cyclophosphamide
to steroids provided no beneﬁt compared with steroids alone
in adults with Henoch Scho¨nlein purpura (HSP) nephritis.1 In
this study, however, they did not mention an impor-
tant randomized controlled study of cyclophosphamide in
children with severe HSP nephritis, showing there were no
differences in outcome between the two groups (supportive
therapy with or without oral cyclophosphamide 90mg/m2 per
day for 42 days).2
We speculate that cyclophosphamide might provide no
beneﬁt in the patients studied by Pillebout et al. on the basis
of the drug-related characteristics of decreasing ﬁbrinolytic
activity. Although not extensively studied yet, we previously
reported that ﬁbrinogen deposition is closely related to the
formation of crescents and severe renal injury in HSP
nephritis3 and Bazzan et al. demonstrated that a signiﬁcant
decrease in plasma ﬁbrinolytic activity was observed after
cyclophosphamide therapy.4 Therefore, there is a possibility
that ﬁbrinogen deposition by decreased ﬁbrinolytic activity
after cyclophosphamide use might inﬂuence the renal
outcome in HSP nephritis.
Furthermore, cyclophosphamide was administered in
combination with urokinase (ﬁbrinolytic agent) to severe
HSP nephritis patients; it resulted in not only more reduction
of proteinuria but also lower activity and chronicity index at
follow-up renal biopsies than in those who were not treated
with cyclophosphamide.5
Therefore, it would be interesting if ﬁbrinogen deposition
and crescent formation are evaluated before and after
cyclophosphamide therapy, although it was not carried out
in the patients studied by Pillebout et al.1 Further studies
should be performed to elucidate the effects of cyclopho-
sphamide on intraglomerular coagulation in patients with
HSP nephritis.
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